EPHA10 and neoplasm: Furthermore, the in vivo efficacy of dimeric BsAb (EphA10/CD3) in a xenograft model showed that it could inhibit tumor growth at low doses (1, 10 μg), similar to the effective concentration ranges for other BsAbs [22, 29].